Navigation Links
Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
Date:12/9/2009

WALTHAM, Mass., Dec. 9 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) reported today top-line results from a Phase 3 clinical trial to evaluate the safety and efficacy of RG1068, synthetic human secretin, to improve magnetic resonance imaging (MRI) of the pancreas in patients with a history of pancreatitis. The study's co-primary endpoints were improvements in sensitivity of detection of structural abnormalities of the pancreatic ducts using RG1068 in combination with MRI compared to MRI alone with minimal loss in specificity (<7.5%). The study design used endoscopy as the standard for determination of structural abnormalities. The predetermined criteria for a successful study were achievement of a statistically significant improvement in sensitivity with minimal loss in specificity from two of the three central radiologists reading the MRI images. In this study, one radiologist achieved a statistically significant improvement in sensitivity with RG1068 (p<0.001) while a second radiologist showed a trend but did not achieve statistical significance (p=0.088). There was minimal loss in specificity for all radiologists. While it was not a pre-specified endpoint, pooled data from all three radiologists resulted in a statistically significant improvement in sensitivity with RG1068 (p=0.005) with minimal loss in specificity.

The RG1068-enhanced MRI images showed highly statistically significant improvements on other endpoints for all radiologists including improvements in image quality (p<0.001), ability to see all three segments of the pancreatic duct (p<0.001), and physician confidence in their ability to identify pancreatic duct abnormalities (p<0.001), when compared to MRI alone. There were no serious adverse events (SAEs) associated with the RG1068-MRI procedures compared to 55 SAEs associated
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
2. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
3. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
4. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
5. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
6. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
7. TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting
8. Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution
9. Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis
10. NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico
11. ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) announces that ... the Board of Directors of his decision to step down from ... of Severn Trent plc.  James will leave Shire at the end ... a new CFO immediately. Flemming Ornskov, Shire,s Chief Executive ... high-quality finance team at Shire. We are very grateful to him ...
(Date:10/17/2014)... Oct. 17, 2014 With the recent ... function has come across several challenges in creating ... managing globalization.  The Medical ... dedicated to providing benchmarking and best practices across ... is a service composed of three stages: 1) ...
(Date:10/17/2014)... Research ... addition of the  "China Interventional Cardiovascular Device ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) The ... China impacted by accelerated aging ... dietary habit, way of working and other ...
Breaking Medicine Technology:Interim Chief Financial Officer James Bowling to Step Down 2Interim Chief Financial Officer James Bowling to Step Down 3Interim Chief Financial Officer James Bowling to Step Down 4Early Key Findings from the Medical Affairs Consortium Research 2China Interventional Cardiovascular Device Industry Report 2014-2017 2China Interventional Cardiovascular Device Industry Report 2014-2017 3
... The oncology therapeutic area continues to be an ... as next generation oncology therapies find success in a ... success, organizations in the oncology therapeutic area are facing ... the factors that play the biggest role in the ...
... Caliper Life Sciences, Inc. (NASDAQ: CALP ... second quarter financial results at 5:00 pm Eastern (2:00 ... President and Chief Executive Officer, and Peter McAree, Chief ... operational and financial results and the company,s outlook for ...
Cached Medicine Technology:Success Factors and Failure Points for Oncology New Product Launches 2Caliper Life Sciences' Second Quarter Results Conference Call Notice 2
(Date:10/19/2014)... 20, 2014 The leading review ... http://www.top10bestseohosting.com/go/iPage/ ) and GreenGeeks are the best Dedicated ... for those who want to buy high quality ... , The IT manager of Top10BestSEOHosting.com says, “We ... recommended suppliers for everyone. A lot of the ...
(Date:10/19/2014)... Dallas, Texas (PRWEB) October 20, 2014 ... therapeutic development for Partial Seizure, complete with comparative ... target, mechanism of action (MoA), route of administration ... and featured news and press releases. It also ... for Partial Seizure and special features on late-stage ...
(Date:10/19/2014)... 20, 2014 Recently, Fancyflyingfox.com, an innovative ... clothes, has announced its latest designs of 2014 ... the new elegant outfits are offered with big discounts, ... order before October 30 can enjoy this special offer. ... marketing strategies, it has become one of the leading ...
(Date:10/19/2014)... Stephen T. Greenberg, M.D., with offices in Woodbury, Southampton and ... as one of Long Island’s best cosmetic surgeons. In ... the best provider for Botox injections. Glisten, his Skin & ... best Laser Treatment center on Long Island.* , The voting ... the contest once per day, per IP address. , Stephen ...
(Date:10/19/2014)... 2014 – The U.S. Government has initiated a ... disease by 2025. However, a workgroup of nearly ... milestones in the U.S. Government,s National Plan to ... increased in scale, and adequately funded in order ... proposals by the workgroup to enlarge and strengthen ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Dr. Stephen T. Greenberg – Nominated for the 10th Consecutive Year for One of Long Island’s Best Cosmetic Surgeons for 2015 by the Long Island Press 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 3Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 4Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 5Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 6
... Reinberg HealthDay Reporter , MONDAY, Nov. 14 (HealthDay ... needed medications if they,re free, U.S. researchers find. Less ... their prescribed medications, which increases hospitalizations, deaths and costs to ... if eliminating the co-pay fee might entice more patients to ...
... may be making premature predictions about which patients are ... even withdrawing care -- before the window in which ... likely to wake up, according to two new studies ... of Pennsylvania. The research helps to better define the ...
... Women with the deadliest and rarest form of breast cancer ... were severely limited, thanks to a new discovery by George ... called "inflammatory breast cancer," kills about half the women who ... mere 18 months after diagnosis. About 10,000 women are diagnosed ...
... Scientists presented new research today demonstrating the impact life ... examine how such environmental information can be transmitted from ... as epigenetics. This new knowledge could ultimately improve understanding ... how a parent,s exposure to drugs, alcohol, and stress ...
... of therapeutic hypothermia and delay in return of spontaneous ... measurable blood pressure, were both associated with poor neurologic ... study being presented Nov. 14 at the at the ... Also, caregivers who have an appropriate understanding of the ...
... Reporter , SUNDAY, Nov. 13 (HealthDay News) -- Tragic stories ... on the playing field due to an undetected heart problem. ... aimed at helping doctors and coaches detect these problems early ... suggests that only a small percentage of physicians are heeding ...
Cached Medicine News:Health News:More Heart Attack Patients Take Meds When They Are Free 2Health News:More Heart Attack Patients Take Meds When They Are Free 3Health News:Withdrawal of care may occur too soon in cardiac arrest patients who receive hypothermia treatment 2Health News:Withdrawal of care may occur too soon in cardiac arrest patients who receive hypothermia treatment 3Health News:George Mason University research gives hope to women with deadliest breast cancer 2Health News:George Mason University research gives hope to women with deadliest breast cancer 3Health News:Nature and nurture work together to shape the brain 2Health News:Better understanding of neurologic defects improves post-cardiac-arrest discharge 2Health News:Too Few Doctors Screen Young Athletes for Hidden Heart Trouble 2Health News:Too Few Doctors Screen Young Athletes for Hidden Heart Trouble 3
... of guiding introducers includes Swartz™ Series, ... piece steerable, all designed for the ... varying curves and longer sheath lengths ... Jude Medical guiding introducers are designed ...
Lumenis 1000 Integrated Slit Lamp Fully-integrated biomicroscope slit lamp laser delivery system, complete with built-in LaserLink, parallel optics, magnification changer, micromanipulator and multi...
Novus 30001 A fully-integrated and powerful 532 nm Operating Room Photocoagulator with reliable DPSS technology and simplified operation using a touch screen interface and remote control....
... Selecta Trio The pinnacle ... Nd:YAG, diode-pumped solid-state (DPSS) 532 ... laser (SLT) and offering maximum ... The first and only Nd:YAG, ...
Medicine Products: